



TB Times

Mayo Clinic Center for Tuberculosis (MCCT)

UPCOMING EVENTS

Select links for details

[MCCT Innovations in TB: TB Diagnostic Strategies](#)

April 26, 2024
Webinar

[TB Lunch and Learn Series](#)

Select Thursdays
Virtual

[Wisconsin TB Summit Virtual Series](#)

April 2, 9, 16, 23, 30
[Past Sessions Recorded!](#)

[Kansas ID Symposium](#)

May 9-10, 2024
Overland Park, KS
In-person

[2024 Civil Surgeons Webinar Series](#)

June 20, 2024
Webinar

[TB ETN and TB PEN Conference](#)

September 17-19, 2024
Atlanta, GA
In-person

[TB Clinical Intensive](#)

[New Date!](#) October 9-10, 2024
Rochester, MN
In-person

[Iowa TB Clinical Intensive](#)

October 24-25, 2024
Des Moines, IA
In-person



2024 TB Champions!

The CDC recently announced the [2024 CDC U.S. TB Elimination Champions](#), and it comes as no surprise to see so many individuals from the MCCT region receive this honor. Collaborating with many of you, it's evident the dedication and passion present in our collective efforts. Congratulations to those who received this prestigious award!



We also extend recognition to everyone in our region, spanning Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, Oklahoma, South Dakota, Texas, and Wisconsin, for their significant contributions to TB elimination, both locally and beyond.

Compounding Pharmacy Fact Sheet Just Released



MCCT has just released a [Compounding Pharmacy Fact Sheet](#) designed to assist clinicians, TB program staff, and individuals interested in understanding the role of compounding pharmacies in supporting the treatment of patients with TB disease or LTBI. This one-page document addresses key questions and includes valuable resources, such as compounding pharmacy website links.




Mayo Clinic Talks “TB” Podcast

Mayo Clinic Center for Tuberculosis just released its inaugural podcast on the ‘Mayo Clinic Talks’ platform to commemorate World TB Day. This podcast, titled “[Tuberculosis](#),” runs for approximately 30 minutes and is a poignant tribute to World TB Day and Dr. Robert Koch’s pivotal discovery. Through this episode, we aim to delve into the disease, its diagnosis and management with infectious disease specialist and Professor of Medicine, Zelalem Temesgen, M.D., from the Mayo Clinic. It’s thought that a variant of tuberculosis originated in East Africa around 3 million years ago with the current strain of *Mycobacterium tuberculosis* dating back at least 20,000 years. Although easily spread from one person to another, not everyone infected develops active disease. The management of tuberculosis varies, and although there is a vaccine, it’s not commonly used in the U.S. Effective pharmacologic treatment is available, however drug-resistant strains have presented challenges in some cases.

Journal Spotlight

[Patient perceptions of video directly observed therapy for tuberculosis: A systematic review](#)

Virtual modes of TB treatment monitoring have become increasingly relevant in the last decade with the advancements and increasing accessibility of technology. Read this systematic review published in the *Journal of Clinical TB* comparing people with TB’s perceptions of standard directly observed therapy (DOT) versus video directly observed therapy (vDOT).




[Adjunctive Dexamethasone for Tuberculosis Meningitis in HIV-Positive Adults](#)

Adjunctive glucocorticoids are widely used to treat human immunodeficiency virus (HIV)-associated tuberculous meningitis despite limited data supporting their safety and efficacy. Learn more in a study highlighted in the *New England Journal of Medicine* on this important topic.



New IDCCrowd Help Feature

Need help with [IDCCrowd](#)? There is a new “help” icon at the bottom of the page in the IDCCrowd software, which is like a live chat for technical assistance. You can also submit your technical query with IDCCrowd and the team will get back to you.



WHO Highlights

[TPT: Rapid Communication](#)

In this [Rapid Communication](#), WHO is announcing a number of updates to its 2nd edition of the guidance on tuberculosis preventive treatment (TPT). Most prominently, a regimen of 6 months of levofloxacin should now be used as TPT for contacts of MDR/RR-TB considering new evidence from two well-conducted randomized controlled trials in South Africa and Vietnam supporting the use of levofloxacin of this regimen in people of all ages. These updates will help stakeholders prepare for changes that will be introduced when the updated guidelines are released later this year.

[Roadmap in Ending TB in Children and Adolescents](#)

The [Roadmap towards ending TB among children and adolescents, third edition](#) builds on the 2013 and 2018 versions. The 2023 version recognizes the progress made over the past five years and outlines priorities and key actions designed to accelerate progress towards the targets elaborated during the 2023 United Nations General Assembly High-Level Meeting on the fight against TB. The 2023 Roadmap retains the strong focus on TB in children, while also emphasizing the importance of addressing TB among adolescents, and for the first time, among pregnant and post-partum women.



INNOVATIONS IN TUBERCULOSIS Webinar Series

4th Friday of every month

[Learn More Here](#)

This free monthly webinar series offers healthcare professionals the latest insights in tuberculosis (TB). Tuberculosis experts will discuss screening, diagnosis, and treatment of TB disease and latent TB infection (LTBI). Topics include considerations for pediatric and adult populations, clinical updates, diagnostic methods, and treatment strategies. Healthcare professionals managing patients with TB can stay informed on research developments and emerging treatment regimens for active TB and LTBI, exploring innovative approaches to enhance patient adherence and outcomes.

Newsletter Content Suggestions

We invite you to be active participants in shaping the content of our newsletter. We will do our best to provide clarity on your TB related questions and include topics and events you would like to showcase. Simply submit your ideas to [TB Times Content Suggestion](#). Each issue we will feature suggested content, making this newsletter a true reflection of your needs.

Vision

To become a regionally, nationally, and internationally recognized Center of Excellence for tuberculosis.

Mission

To contribute, in a meaningful way, to the control, management, and elimination of tuberculosis regionally, nationally, and globally.



Medical Consultation

MCCT provides expert medical consultation to public health and medical professionals in our assigned region. We have colleagues with expertise in public health nursing, pharmacy, laboratory, occupational health, pediatrics, and radiology just to name a few.

Consultations can be requested using one of the following options:

- Submit at [IDCrowd Platform](#)
- Email tbcenter@mayo.edu
- Call 507-284-0275

IDCrowd is a new platform for submitting requests used by all TB COEs. If you are using IDCrowd for the first time, choose the option to register for a new membership. Additional information on how to submit a request can be found [here](#).

Mini Fellowships

As part of the TB COE initiatives, MCCT is providing mini-fellowship opportunities for healthcare professionals seeking to deepen their understanding of TB.

Experiences will be curated to meet individual learning needs. Some experiences that may be offered include shadowing healthcare professionals as they interact with patients, observing directly observed therapy (DOT), and participating in TB case reviews.

You can find out more information by emailing tbcenter@mayo.edu. To be considered for a mini fellowship, please submit an [application here](#).

Educational Requests

MCCT is able to support a variety of TB related needs including virtual and in-person training, educational material development, and technical assistance. Please contact us to discuss ways we can support your work in treating and preventing tuberculosis.

Contact Us



TBcenter@mayo.edu



centerfortuberculosis.mayo.edu



507-284-0275